Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesMineral Metabolism and Bone Disease
You have accessRestricted Access

Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients

Csaba P. Kovesdy, Miklos Z. Molnar, Maria E. Czira, Anna Rudas, Akos Ujszaszi, Laszlo Rosivall, Miklos Szathmari, Adrian Covic, Andras Keszei, Gabriella Beko, Peter Lakatos, Janos Kosa and Istvan Mucsi
CJASN December 2010, 5 (12) 2297-2304; DOI: https://doi.org/10.2215/CJN.03520410
Csaba P. Kovesdy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miklos Z. Molnar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria E. Czira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Rudas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akos Ujszaszi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo Rosivall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miklos Szathmari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian Covic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andras Keszei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriella Beko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Lakatos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janos Kosa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Istvan Mucsi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives: Obesity is associated with increased parathyroid hormone (PTH) in the general population and in patients with chronic kidney disease (CKD). A direct effect of adipose tissue on bone turnover through leptin production has been suggested, but such an association has not been explored in kidney transplant recipients.

Design, setting, participants, & measurements: This study examined associations of serum leptin with PTH and with biomarkers of bone turnover (serum beta crosslaps [CTX, a marker of bone resorption] and osteocalcin [OC, a marker of bone formation]) in 978 kidney transplant recipients. Associations were examined in multivariable regression models. Path analyses were used to determine if the association of leptin with bone turnover is independent of PTH.

Results: Higher leptin levels were associated with higher PTH and lower vitamin D levels, and adjustment for vitamin D attenuated the association between leptin and PTH. However, higher leptin was also significantly associated with lower levels of the bone turnover markers: 1 SD higher leptin was associated with 0.13 lower log-OC (−0.17, −0.08, P < 0.001) and 0.030 lower log-CTX (−0.045, −0.016, P < 0.001) after multivariable adjustments. Path analysis indicated that the association of leptin with PTH was mostly mediated through vitamin D, and that the association between leptin and bone turnover was independent of PTH and vitamin D.

Conclusions: Elevated leptin level is associated with lower bone turnover independent of its effects on serum PTH in kidney transplant recipients.

Secondary hyperparathyroidism (SHPT) develops early in the course of chronic kidney disease (CKD) (1), and it has been associated with higher cardiovascular morbidity (2) and mortality (3) in hemodialysis patients and with higher mortality in patients with nondialysis-dependent CKD (4). In addition to factors directly related to worsening kidney function (e.g., abnormalities in calcium, phosphorus, vitamin D, and FGF23 metabolism) (1,5–8), PTH levels are also affected by demographic (9,10) and co-morbidity characteristics (11) in CKD. There is mounting evidence that obesity is also associated with higher PTH levels in the general population (12–16) and in patients with CKD (17,18). Furthermore, measurements of body composition suggest that the higher PTH associated with elevated body mass index (BMI) is directly related to the higher adiposity of these individuals (16). There have been speculations that obesity and adiposity indirectly cause elevated PTH levels by affecting vitamin D metabolism (15,19). This would logically imply a consequent increase in bone turnover mediated by PTH. More recently it has been suggested that adipose tissue may also exert a direct effect on bone tissue, possibly mediated through leptin secretion (20), providing an explanation for the decrease in bone turnover reported by some studies in obese individuals, despite relatively higher PTH levels (12). Earlier studies in dialysis patients reported an inverse association between leptin level and bone turnover (21,22). It is unclear if similar associations are present in kidney transplant recipients, a population that is also characterized by distinct changes in bone metabolism (23–26).

The gold standard of determining bone turnover is bone histology, but this method is not feasible for application in large groups of patients. Possible alternatives to bone histology are biochemical markers of bone turnover such as serum beta crosslaps (CTX)—the C-terminal telopeptide fragments of type I collagen, a marker of bone resorption (27), or serum osteocalcin (OC) and serum alkaline phosphatase (ALP), markers of bone formation (28,29). To test the hypothesis that leptin may be directly associated with bone metabolism rather than through its effects on PTH, we examined the association of serum leptin with serum PTH level and with biochemical markers of bone resorption and formation in a large prevalent cohort of kidney transplant recipients.

Materials and Methods

All stable adult outpatient renal allograft recipients (n = 1214) who were followed at the Department of Transplantation and Surgery at Semmelweis University, Budapest, Hungary on December 31, 2006 were evaluated for inclusion. Patients with a current hospitalization or an acute rejection within the preceding 4 weeks, those who underwent transplantation in the previous 3 months, and those with acute infection or bleeding were excluded. Two hundred and five patients (17%) refused to participate in the study and 16 (1%) patients satisfied exclusion criteria. Fifteen patients (1%) were excluded because of missing relevant data points; the final study population consisted of 978 patients.

Assessments were conducted between February 2007 and August 2007 (Malnutrition-Inflammation in Transplant—Hungary Study [MINIT-HU Study]) and included the recording of demographics, comorbidities, medication use, and anthropometric measurements including BMI and abdominal circumference (AC) in a single session. Routinely available laboratory data were extracted from the patients' charts and from the hospital's electronic laboratory database. GFR was estimated using the abbreviated equation developed for the Modification of Diet in Renal Disease study (30) and categorized according to the staging system introduced by the Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for CKD: Evaluation, Classification, and Stratification (31).

Serum parathyroid hormone (PTH), 25-hydroxy vitamin D (25OHD), CTX, OC, ALP, C-reactive protein (CRP), and IL-6 levels were measured at the time of enrollment from a single morning fasting blood collection. Intact PTH was measured by the Elecsys PTH STAT Assay (Elecsys System; Roche, Mannheim, Germany; reference range 15 to 65 pg/ml) using a sandwich test principle in which a biotinylated monoclonal antibody reacts with the N-terminal fragment (1–37) and a monoclonal antibody labeled with a ruthenium complex reacts with the C-terminal fragment (38–84) (32). Serum CTX were measured on a Roche Elecsys 1010 analyzer (Elecsys System; Roche, Mannheim, Germany; reference range 0 to 0.32 ng/ml) by an electrochemiluminescence immunoassay method. Serum leptin was measured using a solid-phase sandwich ELISA method (R&D Systems, Minneapolis, MN), serum OC was measured by a sandwich ELISA method (N-MID Osteocalcin assay, Elecsys System; Roche, Mannheim, Germany), and serum total 25OHD was measured with a direct competitive chemiluminescence immunoassay (“LIAISON 25 OH Vitamin D Total,” DiaSorin, Inc., Stillwater, MN).

After descriptive statistics skewed variables (serum PTH, 25OHD, CTX, OC, and leptin) were natural log-transformed, obesity was assessed by measuring BMI and AC. Correlation coefficients were used to determine the association among BMI, AC, and serum leptin levels and among PTH, 25OHD, CTX, OC, and ALP levels. The association of leptin with PTH, CTX, OC, and ALP levels was assessed in separate linear regression models, with adjustments for covariates believed to be important confounders (age; gender; diabetes mellitus; use of beta blockers; dose of steroids, cyclosporine A, and tacrolimus; estimated GFR; and serum calcium, phosphorus, 25OHD, CRP, and IL-6) (17). PTH, CTX, OC, and ALP were treated as dependent variables in all models. The multivariable-adjusted geometric means or means of PTH, CTX, OC, and ALP by quartiles of serum leptin were estimated from the multivariable regression models using STATA postestimation commands (ADJUST). To determine if the PTH-vitamin D axis mediates the associations between leptin and bone turnover, we created separate regression models assessing associations of leptin with markers of bone turnover after adjustment for PTH and vitamin D levels (33). To better describe the complex interrelationship between leptin, 25OHD, PTH, and bone turnover, we performed path analyses using the maximum likelihood method for parameter estimation (34). Various models were tested using assumptions of different directions of effect between leptin, PTH, 25OHD, CTX, and OC. More complex models including age, BMI, GFR, ALP (as an additional marker of bone formation along with OC), calcium, and phosphorus were also tested, but effect estimates did not change substantially and hence the most parsimonious model was selected. A range of goodness-of-fit statistics were computed to assess model fits, including model χ2, goodness-of-fit index (GFI), adjusted goodness-of-fit index (AGFI), Bentler comparative fit index (CFI), root mean square error of approximation (RMSEA), and the standardized root mean square residual (SRMR) (34).

We performed secondary analyses to incorporate blood levels of cyclosporine and tacrolimus in multivariable models. Interactions with gender and with estimated GFR were explored by examining associations separately in men and women and in subgroups of patients divided by their level of estimated GFR and by including interaction terms in regression models. P values of <0.05 were considered significant. Statistical analyses were performed using STATA version 10 (STATA Corporation, College Station, TX) and Amos version 16.0 (SPSS, Inc., Chicago, IL). The Institutional Review Board of Semmelweis University approved the study protocol.

Results

Baseline characteristics of all patients and of patients grouped according to their leptin levels are shown in Table 1. Overall, 65% of patients were classified as having CKD stages 3 or 4. Patients with higher serum leptin level were older, were more likely to be female, had higher BMI and AC, used calcitriol more frequently, and were administered lower doses of cyclosporine A. Doses of steroids and tacrolimus and blood levels of cyclosporine A and tacrolimus were not different in patients with higher and lower leptin levels. Patient with higher serum leptin also had shorter dialysis vintage; lower estimated GFR, vitamin D, CTX, and OC levels; and higher PTH, CRP, and IL6 levels.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of the entire cohort and of patients divided by their serum leptin level

Tables 2 and 3 show correlation coefficients for markers of obesity and inflammation (Table 2) and for biochemical markers of CKD-mineral and bone disorder (Table 3). Markers of obesity and adiposity (BMI, AC, and leptin) correlated significantly with each other (P < 0.0001 for all, Table 2). CRP and IL-6 also correlated significantly with each other, and CRP showed a modest but significant correlation with BMI and AC; a similar correlation was seen between IL-6 and AC (Table 2). Biochemical markers of CKD-mineral and bone disorder all showed significant correlations, with the exception of calcium and phosphorus versus ALP and calcium versus OC (Table 3). Figure 1 shows unadjusted and adjusted estimated PTH levels in groups divided along quartiles of serum leptin. Higher leptin showed an association with higher PTH, which was attenuated after adjustments, especially for serum 25OHD levels. Figures 2 and 3 show unadjusted and adjusted estimated serum CTX (Figure 2) and OC (Figure 3) levels in groups divided by quartiles of serum leptin. Higher leptin levels were associated with significantly lower serum CTX and OC, even after adjustment for PTH and vitamin D. Associations between leptin and ALP were similar to those seen for OC (results not shown). The association between leptin and PTH was more pronounced in men (1 μg/L higher leptin was associated with 0.006 log-unit higher PTH in men [95% confidence interval {CI}: 0.003 to 0.01, P = 0.001] and 0.0009 log-units higher PTH in women [95% CI: −0.001 to 0.003, P = 0.4]), but the interaction term was NS (P = 0.2). No significant gender interaction was detected for the association between leptin and markers of bone turnover. There was also no interaction with GFR for any of the studied associations (data not shown). In path analyses, the best fit was seen for the model assuming a positive effect of leptin on PTH that was almost entirely mediated by 25OHD and a direct negative effect independent of PTH and 25OHD on bone turnover (Figure 4). Goodness-of-fit statistics for this model suggested a reasonably good fit (model χ2: 58.765 [P < 0.001], RMSEA: 0.098, GFI: 0.979, AGFI: 0.928, CFI: 0.957, and SRMR: 0.0451).

View this table:
  • View inline
  • View popup
Table 2.

Pairwise correlation coefficients and significance levels for various markers of obesity, adiposity, and inflammation

View this table:
  • View inline
  • View popup
Table 3.

Pairwise correlation coefficients and significance levels for serum PTH, ALP, and CTX

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Unadjusted (model 1) and estimated multivariable adjusted (models 2 and 3) intact PTH levels (95% CI) in patients with different quartiles of serum leptin. Intact PTH levels were adjusted for age, gender, diabetes mellitus, transplant vintage, estimated GFR, corrected calcium, phosphorus, CRP, IL-6, use of beta blockers, doses of administered corticosteroids, cyclosporine A, and tacrolimus (model 2), and serum vitamin D level (model 3). Comparisons between the PTH levels in the different quartiles of serum leptin were performed in regression models with patients in the first quartile serving as referent, with adjustment for the listed variables in the respective models. *P < 0.05.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Unadjusted (model 1) and estimated multivariable adjusted (models 2 and 3) serum CTX levels (95% CI) in patients with different quartiles of serum leptin. Serum CTX levels were adjusted for age, gender, diabetes mellitus, transplant vintage, estimated GFR, corrected calcium, phosphorus, CRP, IL-6, use of beta blockers, doses of administered corticosteroids, cyclosporine A, and tacrolimus (model 2), and serum PTH and vitamin D level (model 3). Comparisons between the serum CTX levels in the different quartiles of serum leptin were performed in regression models with patients in the first quartile serving as referent, with adjustment for the listed variables in the respective models. **P < 0.01, ***P < 0.001.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Unadjusted (model 1) and estimated multivariable adjusted (models 2 and 3) serum OC levels (95% CI) in patients with different quartiles of serum leptin. Serum OC levels were adjusted for age, gender, diabetes mellitus, transplant vintage, estimated GFR, corrected calcium, phosphorus, CRP, IL-6, use of beta blockers, doses of administered corticosteroids, cyclosporine A, and tacrolimus (model 2), and serum PTH and vitamin D level (model 3). Comparisons between the OC levels in the different quartiles of serum leptin were performed in regression models with patients in the first quartile serving as referent, with adjustment for the listed variables in the respective models. *P < 0.05, ***P < 0.001.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Path model describing the effect of leptin on serum PTH, 25OHD, OC, and CTX. Arrows represent direct effects. Numbers on the arrows represent standardized regression coefficients with P values, and the numbers on the boxes represent squared multiple correlations.

Discussion

We describe robust associations of serum leptin with markers of bone resorption (CTX) and formation (OC and ALP) independent of PTH and vitamin D levels in a large transplant sample with various levels of kidney function. We also detected a direct association between leptin and PTH and an attenuation of this association with adjustment for serum 25OHD levels. Importantly, our analyses suggest that leptin has a direct negative effect on bone turnover independent of its concomitant positive association with PTH.

Previous studies in patients with normal kidney function showed that higher BMI was associated with elevated PTH and lower 25OHD levels (13–16), suggesting that the mechanism behind the higher PTH level seen in obese individuals may have been via a direct effect of adiposity on vitamin D metabolism. More recently it was suggested that by virtue of its endocrine functions, adipose tissue may also exert a direct effect on bone metabolism (20). Indeed, recent studies of patients who underwent weight-reducing surgery for obesity reported a decrease in leptin levels and increased bone turnover after significant weight loss (35,36). PTH levels remained unchanged in one of these studies (35) and decreased significantly in the other (36). Leptin, which is a hormone secreted by fat cells and is involved in energy homeostasis (37), was shown to affect bone turnover, possibly through its effects on hypothalamic β-adrenergic activation and the upregulation of β-adrenergic receptors in bone cells (38), but also directly impacting bone turnover by modulating osteoblast differentiation (39). Extrapolating such findings from the general population to patients with CKD is difficult given the complex nature of CKD-associated changes in bone metabolism. Two studies in hemodialysis-dependent patients reported an inverse association between leptin and biochemically (22) and histologically (21) defined bone turnover, with the findings limited to men only in one these studies (22). To the best of our knowledge, before our study, the effects of leptin on PTH and on bone turnover have not been examined in patients with nondialysis-dependent CKD or in kidney transplant recipients. Our results support and extend the findings of these earlier studies in dialysis patients, including a quantitatively more pronounced association between leptin and PTH (but not between leptin and bone turnover markers) in men. Further studies are needed to clarify a potential gender-specific effect of leptin on PTH secretion. Clarifying the complex associations between adiposity, PTH, and bone turnover in individuals with CKD is especially important because elevated PTH is widely regarded as a marker of high bone turnover and remains an important therapeutic target in this patient population. Because it appears that the effects of adiposity on bone metabolism dissociate from its effects on PTH level, the effect of weight loss or weight gain on bone turnover should not be assessed based on the changes in PTH that occur in this context.

The effects of the above detailed mechanisms on clinical end points are less well defined. General population studies examining the effect of leptin on bone density did not yield a conclusive answer (40–44), possibly because the net effects on bone tissue may depend on other concomitantly acting factors (45). Similar studies have not yet been performed in patients with CKD or in kidney transplant recipients, and no studies have examined the effect of the complex interrelationship between obesity and bone turnover on patient survival. The latter is an especially important question given the opposite association of obesity (46) and SHPT (4) with survival in CKD patients. Future studies could explore if the direct effects of adiposity on bone turnover could serve as an explanation for such discrepancies.

Our study has several limitations. Its cross-sectional design does not allow us to conclude a causal role for leptin in the observed lower bone turnover. However, such a causal relationship can be postulated based on experimental results of animal studies (38) and based on the directionality of the associations seen in our path analyses. We examined Caucasian kidney transplant recipients from a single medical institution; thus, our results may not apply to the transplant population at large or to nontransplant recipients with CKD because bone metabolism and SHPT in transplant recipients is also influenced by factors such as their underlying pretransplant renal bone disease and the various medications received while on dialysis and later as part of their immune suppressant regimen (47). Ideally bone turnover should be assessed using the gold standard of bone biopsy, but such studies are unlikely to be performed in large numbers of patients with various stages of CKD and would thus be less likely to detect smaller effects. We used instead biochemical markers of bone turnover, but it is unclear to what extent these abnormalities correlate with bone histologic patterns in kidney transplant recipients with or without CKD. Serum CTX is accepted as a marker of bone resorption in patients with normal kidney function (27), but it is unknown to what extent it is diagnostic of histologically defined high turnover bone disease in kidney transplant recipients with or without CKD, especially because levels of CTX are also influenced by kidney function (48). However, we have found similar results when examining other serum markers of bone turnover, such as serum OC levels, an accepted marker of bone formation (28). Because of the uncertain meaning of elevated biochemical bone turnover marker levels on bone health and structure, it remains unclear to what extent leptin levels are associated with histologic abnormalities of the bone in kidney transplant recipients. Finally, we did not have information about the participants' physical activity to explore whether its changes could explain the mechanism of the associations between obesity and bone turnover.

In conclusion, higher serum leptin levels are associated with lower levels of biomarkers of bone resorption and formation and with higher serum PTH levels in kidney transplant recipients. These findings suggest that leptin may exert a direct suppressive effect on bone turnover independent of its effects on PTH. Further research is needed to examine if adiposity can affect bone metabolism and PTH secretion independent of leptin and to determine the practical effect of these novel regulatory pathways.

Disclosures

Dr. Kovesdy has received grants without salary support from Abbott, Genzyme, and Shire and honoraria from Genzyme.

Acknowledgments

Part of this material was presented in abstract form at the annual meeting of the American Society of Nephrology; October 27 through November 1, 2009; San Diego, CA. We thank the patients and the staff in the Department of Transplantation and Surgery, Semmelweis University Budapest. This study was supported by grants from the National Research Fund (OTKA; F-68841; HUMAN-MB08-A-81231), ETT (206/09), the Hungarian Kidney Foundation, Hungarian Society of Hypertension, Hungarian Society of Nephrology, and the Foundation for Prevention in Medicine. This paper was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (Drs. Novak and Molnar). Dr. Molnar was recipient of the Hungarian Eötvös Scholarship (MÖB/66-2/2010). The research of Dr. Novak has been supported by an unrestricted research grant from Canadian Home Healthcare, Inc., and the Center for Integrative Mood Research, Toronto, Canada.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received April 22, 2010.
  • Accepted July 8, 2010.
  • Copyright © 2010 by the American Society of Nephrology

References

  1. ↵
    1. Levin A,
    2. Bakris GL,
    3. Molitch M,
    4. Smulders M,
    5. Tian J,
    6. Williams LA,
    7. Andress DL
    : Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007
    OpenUrlCrossRefPubMed
  2. ↵
    1. De Boer IH,
    2. Gorodetskaya I,
    3. Young B,
    4. Hsu CY,
    5. Chertow GM
    : The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 13: 2762–2769, 2002
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Kalantar-Zadeh K,
    2. Kuwae N,
    3. Regidor DL,
    4. Kovesdy CP,
    5. Kilpatrick RD,
    6. Shinaberger CS,
    7. McAllister CJ,
    8. Budoff MJ,
    9. Salusky IB,
    10. Kopple JD
    : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780, 2006
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kovesdy CP,
    2. Ahmadzadeh S,
    3. Anderson JE,
    4. Kalantar-Zadeh K
    : Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73: 1296–1302, 2008
    OpenUrlCrossRefPubMed
  5. ↵
    1. Fajtova VT,
    2. Sayegh MH,
    3. Hickey N,
    4. Aliabadi P,
    5. Lazarus JM,
    6. LeBoff MS
    : Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 57: 329–335, 1995
    OpenUrlCrossRefPubMed
  6. ↵
    1. Martinez I,
    2. Saracho R,
    3. Montenegro J,
    4. Llach F
    : The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29: 496–502, 1997
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pitts TO,
    2. Piraino BH,
    3. Mitro R,
    4. Chen TC,
    5. Segre GV,
    6. Greenberg A,
    7. Puschett JB
    : Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876–881, 1988
    OpenUrlCrossRefPubMed
  8. ↵
    1. St John A,
    2. Thomas MB,
    3. Davies CP,
    4. Mullan B,
    5. Dick I,
    6. Hutchison B,
    7. van der SA,
    8. Prince RL
    : Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 61: 422–427, 1992
    OpenUrlCrossRefPubMed
  9. ↵
    1. Fuleihan GE,
    2. Gundberg CM,
    3. Gleason R,
    4. Brown EM,
    5. Stromski ME,
    6. Grant FD,
    7. Conlin PR
    : Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 79: 1642–1647, 1994
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gupta A,
    2. Kallenbach LR,
    3. Zasuwa G,
    4. Divine GW
    : Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11: 330–334, 2000
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Vincenti F,
    2. Arnaud SB,
    3. Recker R,
    4. Genant H,
    5. Amend WJ Jr..,
    6. Feduska NJ,
    7. Salvatierra O Jr.
    : Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 25: 677–682, 1984
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bell NH,
    2. Epstein S,
    3. Greene A,
    4. Shary J,
    5. Oexmann MJ,
    6. Shaw S
    : Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76: 370–373, 1985
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kamycheva E,
    2. Sundsfjord J,
    3. Jorde R
    : Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. Eur J Endocrinol 151: 167–172, 2004
    OpenUrlAbstract
  14. ↵
    1. Parikh SJ,
    2. Edelman M,
    3. Uwaifo GI,
    4. Freedman RJ,
    5. Semega-Janneh M,
    6. Reynolds J,
    7. Yanovski JA
    : The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 89: 1196–1199, 2004
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wortsman J,
    2. Matsuoka LY,
    3. Chen TC,
    4. Lu Z,
    5. Holick MF
    : Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72: 690–693, 2000
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Snijder MB,
    2. van Dam RM,
    3. Visser M,
    4. Deeg DJ,
    5. Dekker JM,
    6. Bouter LM,
    7. Seidell JC,
    8. Lips P
    : Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. J Clin Endocrinol Metab 90: 4119–4123, 2005
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kovesdy CP,
    2. Ahmadzadeh S,
    3. Anderson JE,
    4. Kalantar-Zadeh K
    : Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin J Am Soc Nephrol 2: 1024–1029, 2007
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Saab G,
    2. Whaley-Connell A,
    3. McFarlane SI,
    4. Li S,
    5. Chen SC,
    6. Sowers JR,
    7. McCullough PA,
    8. Bakris GL
    : Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism 59: 385–389, 2010
    OpenUrlCrossRefPubMed
  19. ↵
    1. Liel Y,
    2. Ulmer E,
    3. Shary J,
    4. Hollis BW,
    5. Bell NH
    : Low circulating vitamin D in obesity. Calcif Tissue Int 43: 199–201, 1988
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kawai M,
    2. Devlin MJ,
    3. Rosen CJ
    : Fat targets for skeletal health. Nat Rev Rheumatol 5: 365–372, 2009
    OpenUrlCrossRefPubMed
  21. ↵
    1. Coen G,
    2. Ballanti P,
    3. Fischer MS,
    4. Balducci A,
    5. Calabria S,
    6. Colamarco L,
    7. Di ZG,
    8. Lifrieri F,
    9. Manni M,
    10. Sardella D,
    11. Nofroni I,
    12. Bonucci E
    : Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis 42: 1036–1042, 2003
    OpenUrlPubMed
  22. ↵
    1. Zoccali C,
    2. Panuccio V,
    3. Tripepi G,
    4. Cutrupi S,
    5. Pizzini P,
    6. Mallamaci F
    : Leptin and biochemical markers of bone turnover in dialysis patients. J Nephrol 17: 253–260, 2004
    OpenUrlPubMed
  23. ↵
    1. Karthikeyan V,
    2. Karpinski J,
    3. Nair RC,
    4. Knoll G
    : The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 4: 262–269, 2004
    OpenUrlCrossRefPubMed
  24. ↵
    1. Monier-Faugere MC,
    2. Mawad H,
    3. Qi Q,
    4. Friedler RM,
    5. Malluche HH
    : High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11: 1093–1099, 2000
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Torres A,
    2. Rodriguez AP,
    3. Concepcion MT,
    4. Garcia S,
    5. Rufino M,
    6. Martin B,
    7. Perez L,
    8. Machado M,
    9. de BE,
    10. Losada M,
    11. Hernandez D,
    12. Lorenzo V
    : Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 13[Suppl 3]: 94–97, 1998
    OpenUrlCrossRefPubMed
  26. ↵
    1. Velasquez-Forero F,
    2. Mondragon A,
    3. Herrero B,
    4. Pena JC
    : Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 11[Suppl 3]: 58–64, 1996
    OpenUrlCrossRefPubMed
  27. ↵
    1. Bonde M,
    2. Qvist P,
    3. Fledelius C,
    4. Riis BJ,
    5. Christiansen C
    : Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80: 864–868, 1995
    OpenUrlCrossRefPubMed
  28. ↵
    1. Power MJ,
    2. Fottrell PF
    : Osteocalcin: Diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 28: 287–335, 1991
    OpenUrlCrossRefPubMed
  29. ↵
    1. Urena P,
    2. Hruby M,
    3. Ferreira A,
    4. Ang KS,
    5. de Vernejoul MC
    : Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7: 506–512, 1996
    OpenUrlAbstract
  30. ↵
    1. Levey AS,
    2. Bosch JP,
    3. Lewis JB,
    4. Greene T,
    5. Rogers N,
    6. Roth D
    : A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461–470, 1999
    OpenUrlCrossRefPubMed
  31. ↵
    K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S266, 2002
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bablok W,
    2. Passing H,
    3. Bender R,
    4. Schneider B
    : A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 26: 783–790, 1988
    OpenUrlPubMed
  33. ↵
    1. Baron RM,
    2. Kenny DA
    : The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173–1182, 1986
    OpenUrlCrossRefPubMed
  34. ↵
    1. Schumacker RE,
    2. Lomax RG
    : A beginner's guide to structural equation modeling, 2nd ed, Mahwah, NJ, Lawrence Erlbaum Associates, Inc., 2004
  35. ↵
    1. Bruno C,
    2. Fulford AD,
    3. Potts JR,
    4. McClintock R,
    5. Jones R,
    6. Cacucci BM,
    7. Gupta CE,
    8. Peacock M,
    9. Considine RV
    : Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: Correlation with the reduction in leptin. J Clin Endocrinol Metab 95: 159–166, 2010
    OpenUrlCrossRefPubMed
  36. ↵
    1. Olmos JM,
    2. Vazquez LA,
    3. Amado JA,
    4. Hernandez JL,
    5. Gonzalez MJ
    : Mineral metabolism in obese patients following vertical banded gastroplasty. Obes Surg 18: 197–203, 2008
    OpenUrlCrossRefPubMed
  37. ↵
    1. Flier JS
    : Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 83: 1407–1413, 1998
    OpenUrlCrossRefPubMed
  38. ↵
    1. Ducy P,
    2. Amling M,
    3. Takeda S,
    4. Priemel M,
    5. Schilling AF,
    6. Beil FT,
    7. Shen J,
    8. Vinson C,
    9. Rueger JM,
    10. Karsenty G
    : Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100: 197–207, 2000
    OpenUrlCrossRefPubMed
  39. ↵
    1. Thomas T,
    2. Gori F,
    3. Khosla S,
    4. Jensen MD,
    5. Burguera B,
    6. Riggs BL
    : Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140: 1630–1638, 1999
    OpenUrlCrossRefPubMed
  40. ↵
    1. Filip R,
    2. Raszewski G
    : Bone mineral density and bone turnover in relation to serum leptin, alpha-ketoglutarate and sex steroids in overweight and obese postmenopausal women. Clin Endocrinol (Oxf) 70: 214–220, 2009
    OpenUrlCrossRefPubMed
  41. ↵
    1. Kim SM,
    2. Kim SH,
    3. Lee JR,
    4. Jee BC,
    5. Ku SY,
    6. Suh CS,
    7. Choi YM,
    8. Kim JG,
    9. Moon SY
    : Association of leptin receptor polymorphisms Lys109Arg and Gln223Arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol 198: 421–428, 2008
    OpenUrlPubMed
  42. ↵
    1. Sato M,
    2. Takeda N,
    3. Sarui H,
    4. Takami R,
    5. Takami K,
    6. Hayashi M,
    7. Sasaki A,
    8. Kawachi S,
    9. Yoshino K,
    10. Yasuda K
    : Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 86: 5273–5276, 2001
    OpenUrlCrossRefPubMed
  43. ↵
    1. Weiss LA,
    2. Barrett-Connor E,
    3. von MD,
    4. Clark P
    : Leptin predicts BMD and bone resorption in older women but not older men: The Rancho Bernardo study. J Bone Miner Res 21: 758–764, 2006
    OpenUrlCrossRefPubMed
  44. ↵
    1. Yamauchi M,
    2. Sugimoto T,
    3. Yamaguchi T,
    4. Nakaoka D,
    5. Kanzawa M,
    6. Yano S,
    7. Ozuru R,
    8. Sugishita T,
    9. Chihara K
    : Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 55: 341–347, 2001
    OpenUrlCrossRefPubMed
  45. ↵
    1. Gordeladze JO,
    2. Reseland JE
    : A unified model for the action of leptin on bone turnover. J Cell Biochem 88: 706–712, 2003
    OpenUrlCrossRefPubMed
  46. ↵
    1. Kovesdy CP,
    2. Anderson JE,
    3. Kalantar-Zadeh K
    : Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 49: 581–591, 2007
    OpenUrlCrossRefPubMed
  47. ↵
    1. Sadideen H,
    2. Covic A,
    3. Goldsmith D
    : Mineral and bone disorder after renal transplantation: A review. Int Urol Nephrol 40: 171–184, 2008
    OpenUrlCrossRefPubMed
  48. ↵
    1. Magnusson P,
    2. Sharp CA,
    3. Magnusson M,
    4. Risteli J,
    5. Davie MW,
    6. Larsson L
    : Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 60: 257–265, 2001
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 5, Issue 12
1 Dec 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients
Csaba P. Kovesdy, Miklos Z. Molnar, Maria E. Czira, Anna Rudas, Akos Ujszaszi, Laszlo Rosivall, Miklos Szathmari, Adrian Covic, Andras Keszei, Gabriella Beko, Peter Lakatos, Janos Kosa, Istvan Mucsi
CJASN Dec 2010, 5 (12) 2297-2304; DOI: 10.2215/CJN.03520410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients
Csaba P. Kovesdy, Miklos Z. Molnar, Maria E. Czira, Anna Rudas, Akos Ujszaszi, Laszlo Rosivall, Miklos Szathmari, Adrian Covic, Andras Keszei, Gabriella Beko, Peter Lakatos, Janos Kosa, Istvan Mucsi
CJASN Dec 2010, 5 (12) 2297-2304; DOI: 10.2215/CJN.03520410
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Mineral Metabolism and Bone Disease

  • Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction
  • Sclerostin and Dickkopf-1 in Renal Osteodystrophy
Show more Mineral Metabolism and Bone Disease

Cited By...

  • Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire